Results 111 to 120 of about 2,882,726 (279)
Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper +7 more
wiley +1 more source
Comparison of siRNA-mediated silencing of glycosaminoglycan synthesis genes and enzyme replacement therapy for mucopolysaccharidosis in cell culture studies [PDF]
Cytotoxicity of laronidase (Aldurazyme®), employed in enzyme replacement therapy (ERT) for mucopolysaccharidosis type I (MPS I) and various siRNAs, tested previously in studies on substrate reduction therapy (SRT) for mucopolysaccharidoses, was ...
Banecka-Majkutewicz, Zyta +5 more
core +2 more sources
Nicotine-replacement therapy: A proven treatment for smoking cessation
Smoking is a major cause of cardiovascular diseases, respiratory diseases and cancer. Despite the high prevalence of smokers worldwide, smokers are often neglected and not offered effective assistance with quitting their habits. In order to overcome this
Noorzurani Md Haris Robson
doaj +1 more source
Abstract Background and aims Tobacco‐free nicotine pouches (NPs) are oral nicotine products promoted by manufacturers and some researchers as tools that may reduce nicotine cravings and support smoking reduction or cessation. However, evidence regarding their actual clinical impact remains limited.
Javad Heshmati +6 more
wiley +1 more source
Abstract Background and aims Oral nicotine pouches (ONPs) have seen a dramatic rise in sales since their introduction to the US market in 2016. We aimed to define the relationship between ONP prices and sales (e.g. price elasticity of demand) and determine how taxes on cigarettes and e‐cigarettes (ECs) impact ONP sales.
Yanyun He +7 more
wiley +1 more source
Has Australia lost control of its tobacco and nicotine markets?
Abstract Background Australia has adopted two policies that the World Health Organization (WHO) recommends as best practice for tobacco control: it has steeply increased tobacco taxes since 2010 and only allowed access to nicotine vapes for medical use.
Ron Borland +4 more
wiley +1 more source
Yasmina Molero,1–3 Johan Zetterqvist,1 Paul Lichtenstein,1 Catarina Almqvist,1,4 Jonas F Ludvigsson1,5–7 1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 2Centre for Psychiatry Research ...
Lichtenstein P +4 more
core
Quitline Queensland: the journey to a globally unique smoking cessation service in Australia
Smoking cessation programs remain a core component of global efforts to reduce smoking and nicotine addiction. Telephone-based counselling, with or without the provision of nicotine replacement therapy, commonly referred to as Quitlines, has been a ...
Joanne Isbel +4 more
doaj +1 more source
With the advent of nicotine replacement therapy, the consumption of the nicotine is on the rise. Nicotine is considered to be a safer alternative of tobacco. The IARC monograph has not included nicotine as a carcinogen.
Aseem Mishra +5 more
doaj +1 more source
Abstract Background and aims On 9 June 2022, Thailand changed its cannabis legislation, expanding access to individuals aged >18 years. Evidence suggests that such changes could increase the risk of cannabis use and related harms, and could influence patterns of use of other substances among adolescents.
Sirada Puetpaiboon +7 more
wiley +1 more source

